October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement

Edward Lee Carter/LinkedIn

Aug 24, 2026, 14:05

Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement

Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared on LinkedIn:

”Anticoagulation stewardship is moving from recommendation to measurement.

The new 2026 AHA/ACC atrial fibrillation performance and quality measures include 5 performance measures and 16 quality measures.

But the bigger story isn’t the number of measures.

It’s what we’re beginning to measure.

For patients with AF, quality increasingly means more than simply:

‘Is the patient anticoagulated?’

The new framework addresses whether we:

Reassess stroke risk annually
Use a DOAC when appropriate for patients at sufficient thromboembolic risk
After PCI, discontinue aspirin within 1–4 weeks in most appropriate patients receiving OAC and P2Y12 therapy, rather than unnecessarily prolonging triple therapy
Use OAC monotherapy in appropriate patients with AF and stable chronic coronary disease >1 year after revascularization
Avoid DOACs where they remain inappropriate, including mechanical valves and moderate-or-greater mitral stenosis

That represents an important evolution.

The question is increasingly:

Is this the right patient, on the right anticoagulant, with the right accompanying antiplatelet therapy, for the right duration — and are we reassessing that decision?

The antiplatelet measures may be particularly valuable.

Medication lists tend to accumulate therapy more easily than they shed it.

Aspirin started appropriately around PCI can remain months – or years – later because nobody revisited the indication.

That creates obvious stewardship opportunities:

AF with OAC and antiplatelet therapy, stable CAD beyond 12 months – reassess the antiplatelet indication.

AF with recent PCI and triple therapy – when should aspirin be stopped?

There is a familiar principle here.

Antimicrobial stewardship taught us to routinely ask:

Why is this drug being used? Is it still necessary? When should it stop?

Antithrombotic therapy deserves similar discipline.

These measures aren’t a complete anticoagulation stewardship program. DOAC dosing, renal-function changes, drug interactions, adherence and bleeding surveillance still require systematic attention.

But the framework gives health systems something important:

Measurable targets.

And measurable targets can become EHR searches, pharmacist interventions, quality dashboards — and ultimately better medication use.

Assess, then Select, Deprescribe, Limit Duration and Reassess

That is anticoagulation stewardship.”

Edward Lee Carter: Anticoagulation Stewardship is Moving From Recommendation to Measurement